Reading the presentation, I was reminded of the Arrowhead Research concerning homing peptides:
http://www.arrowheadresearch.com/technology/homing-peptides
Delivery of canonical (and especially certain classes of non-canonical) siRNA is a very big business.
This could be an "market disruptive" development that PYC could exploit.
Silencing siRNA (over a protein class) could lead the way for targetted therapeutics for Phylomers (silencing over a protein "phase").
Hence there is potential for PYC to participate in markets around siRNA delivery - which is currently a very lucrative place to be.
boston tides presentation, page-5
-
- There are more pages in this discussion • 73 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
-0.010(7.69%) |
Mkt cap ! $559.9M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 11.5¢ | $308.5K | 2.533M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 358350 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 371822 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| PYC (ASX) Chart |